Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM2 | P50570 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | CCR4 | P51679 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.43 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28899507 | 0.82 | TLR8 (0.57) | DNM2HRH3 | |
| SCHEMBL11480039 | 0.78 | SCN9A (0.44) | DNM2 | |
| SCHEMBL30268584 | 0.78 | ALDH1A1 (0.58) | DNM2NPC1POLBSLC2A1APOBEC3A | |
| SCHEMBL19477221 | 0.78 | DNM2 (0.80) | DNM2HRH3CCR4 | |
| SCHEMBL19476566 | 0.78 | DNM2 (0.80) | DNM2HRH3CCR4 | |
| SCHEMBL7204411 | 0.76 | CXCR4 (0.55) | HRH3FERMT2 | |
| SCHEMBL1089304 | 0.76 | CXCR4 (0.63) | DNM2HRH3MKNK1 | |
| SCHEMBL1088558 | 0.75 | CXCR4 (0.65) | DNM2HRH3MKNK1 | |
| SCHEMBL1089501 | 0.75 | CXCR4 (0.65) | DNM2HRH3MKNK1 | |
| SCHEMBL11404764 | 0.74 | PDPK1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901119-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-12-02 | — | — | US | disclosed |
| EP-2684039-A2 | PEPTIDE DEFORMYLASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-01-15 | — | — | EP | disclosed |
| US-20130345120-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| WO-2012122450-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345120-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, PEPD, VIP | DNM2 1699/4885HRH3 2507/4885CCR4 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.